BRNS Valuation

Barinthus Biotherapeutics PLC (BRNS) has a current Price-to-Book (P/B) ratio of 0.35. Compared to its 3-year average P/B ratio of 0.43 , the current P/B ratio is approximately -18.80% higher. Relative to its 5-year average P/B ratio of 0.56, the current P/B ratio is about -38.23% higher. Barinthus Biotherapeutics PLC (BRNS) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -70.86%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -50.08% , the current FCF yield is about -100.00% lower.